Impact of leuprolide and goserelin on androgen suppression and adverse events in patients with prostate cancer.
Leuprolide may provide better PSA reduction, but it also leads to more hot flashes compared to goserelin, which has its own cardiovascular risks.
Where it sits
this study against the rest of the goserelin corpusSummary and findings
The study measured the effects of leuprolide (22.5 and 45 mg) and goserelin (10.8 mg) on prostate-specific antigen (PSA) and testosterone levels in 174 patients with prostate cancer over 12 months. Significant reductions in PSA and testosterone levels were observed across treatment groups. Adverse events, particularly hot flashes and cardiovascular events, varied between the two medications.
Abstract
<h4>Background</h4>Androgen deprivation therapy (ADT) is widely employed in the management of advanced prostate cancer, with luteinizing hormone-releasing hormone (LHRH) agonists such as leuprolide and goserelin being common options. However, pharmacological and metabolic differences between these agents may affect the efficacy of hormonal suppression and adverse event profiles. This study compared the effects of leuprolide (22.5 and 45 mg) and goserelin (10.8 mg) on prostate-specific antigen (PSA) and testosterone reduction, as well as their metabolic and cardiovascular impacts and the influence of genetic variants on therapeutic response.<h4>Methods</h4>A prospective, randomized, controlled study was conducted with 174 patients diagnosed with prostate cancer and treated with ADT for 12 months. Serum PSA and testosterone levels, lipid and glycemic profiles, and adverse events were monitored. Genetic analyses were performed to identify mutations in the TP53, BRCA1, BRCA2, and ATM genes.<h4>Results</h4>All treatment groups exhibited significant reductions in PSA and testosterone levels. Leuprolide 22.5 mg achieved the most pronounced PSA reduction, whereas goserelin 10.8 mg demonstrated greater variability in testosterone during the early months of therapy. Hot flashes were the most frequent adverse event, reported in 90% of patients treated with leuprolide 22.5 mg, while cardiovascular events were more prevalent in the goserelin 10.8 mg group. The TP53 gene was the most frequently altered (20.4%), followed by BRCA2 (7.4%) and ATM (6.5%), though these mutations did not significantly affect treatment response.<h4>Conclusion</h4>ADT effectively achieves hormonal suppression in prostate cancer; however, differences between LHRH agonists influence clinical and metabolic outcomes. Leuprolide 22.5 mg showed superior PSA reduction but higher rates of vasomotor symptoms and weight gain, while goserelin 10.8 mg was associated with hormonal instability and cardiovascular risk. Genetic findings suggest that BRCA2 variants may affect lipid metabolism, reinforcing the need for personalized ADT strategies integrating metabolic and genetic profiles.
Background
This paper addresses the comparative effects of leuprolide and goserelin, both luteinizing hormone-releasing hormone (LHRH) agonists, in androgen deprivation therapy (ADT) for advanced prostate cancer. Prior knowledge indicates that these agents can suppress androgen levels, but differences in their pharmacological profiles may influence efficacy and adverse effects. Understanding these differences is crucial for optimizing treatment strategies in prostate cancer management.
Methods
A prospective, randomized, controlled study was conducted with 174 patients diagnosed with prostate cancer who underwent ADT for 12 months. The study monitored serum PSA and testosterone levels, lipid and glycemic profiles, and adverse events. Genetic analyses were performed to identify mutations in TP53, BRCA1, BRCA2, and ATM genes.
Results
All treatment groups exhibited significant reductions in PSA and testosterone levels. Leuprolide 22.5 mg achieved the most pronounced PSA reduction, while goserelin 10.8 mg showed greater variability in testosterone levels during the early months of therapy. Hot flashes were reported by 90% of patients treated with leuprolide 22.5 mg, and cardiovascular events were more prevalent in the goserelin 10.8 mg group.
Interpretation
The findings suggest that while both leuprolide and goserelin effectively reduce PSA and testosterone levels, leuprolide may offer superior PSA reduction but is associated with higher rates of vasomotor symptoms. The clinical significance of the hormonal variability seen with goserelin and the cardiovascular risks warrants caution. Limitations include the small sample size and the potential impact of genetic variations on treatment responses, which may confound the results.
Key findings
- 90% of patients treated with leuprolide 22.5 mg reported hot flashes.
- Leuprolide 22.5 mg achieved the most pronounced PSA reduction.
- Goserelin 10.8 mg demonstrated greater variability in testosterone during the early months of therapy.
- TP53 gene mutations were the most frequently altered at 20.4%.
- BRCA2 mutations were present in 7.4% of patients.
Limitations
- small n=174
- short follow-up of 12 months
- potential genetic confounding factors
- not all adverse events reported